BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 24746703)

  • 1. Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.
    Chen T; Yang M; Yu Z; Tang S; Wang C; Zhu X; Guo J; Li N; Zhang W; Hou J; Liu H; Han C; Liu Q; Gu Y; Qian C; Wan T; Cui L; Zhu M; Zheng W; Cao X
    Cancer Cell; 2014 May; 25(5):682-96. PubMed ID: 24746703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sef downregulation by Ras causes MEK1/2 to become aberrantly nuclear localized leading to polyploidy and neoplastic transformation.
    Duhamel S; Hébert J; Gaboury L; Bouchard A; Simon R; Sauter G; Basik M; Meloche S
    Cancer Res; 2012 Feb; 72(3):626-35. PubMed ID: 22298595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal.
    Catalanotti F; Reyes G; Jesenberger V; Galabova-Kovacs G; de Matos Simoes R; Carugo O; Baccarini M
    Nat Struct Mol Biol; 2009 Mar; 16(3):294-303. PubMed ID: 19219045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2.
    Piao C; Jin M; Kim HB; Lee SM; Amatya PN; Hyun JW; Chang IY; You HJ
    Oncogene; 2009 May; 28(21):2173-84. PubMed ID: 19398949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.
    Gailhouste L; Ezan F; Bessard A; Frémin C; Rageul J; Langouët S; Baffet G
    Int J Cancer; 2010 Mar; 126(6):1367-77. PubMed ID: 19816936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steady-State Levels of Phosphorylated Mitogen-Activated Protein Kinase Kinase 1/2 Determined by Mortalin/HSPA9 and Protein Phosphatase 1 Alpha in
    Wu PK; Hong SK; Park JI
    Mol Cell Biol; 2017 Sep; 37(18):. PubMed ID: 28674184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential regulation of mitogen-activated protein/ERK kinase (MEK)1 and MEK2 and activation by a Ras-independent mechanism.
    Xu S; Khoo S; Dang A; Witt S; Do V; Zhen E; Schaefer EM; Cobb MH
    Mol Endocrinol; 1997 Oct; 11(11):1618-25. PubMed ID: 9328344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of MEK1 or MEK2 isoform is sufficient to fully transform intestinal epithelial cells and induce the formation of metastatic tumors.
    Voisin L; Julien C; Duhamel S; Gopalbhai K; Claveau I; Saba-El-Leil MK; Rodrigue-Gervais IG; Gaboury L; Lamarre D; Basik M; Meloche S
    BMC Cancer; 2008 Nov; 8():337. PubMed ID: 19014680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK1/2 can feedback-regulate cellular MEK1/2 levels.
    Hong SK; Wu PK; Karkhanis M; Park JI
    Cell Signal; 2015 Oct; 27(10):1939-48. PubMed ID: 26163823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IQGAP1 is a scaffold for mitogen-activated protein kinase signaling.
    Roy M; Li Z; Sacks DB
    Mol Cell Biol; 2005 Sep; 25(18):7940-52. PubMed ID: 16135787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-canonical Small GTPase RBJ Promotes NSCLC Progression Through the Canonical MEK/ERK Signaling Pathway.
    Wang Y; Shen X; Wang Q; Guo Z; Hu L; Dong Z; Hu W
    Curr Pharm Des; 2022; 28(42):3446-3455. PubMed ID: 36397632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf.
    Marzec M; Kasprzycka M; Liu X; Raghunath PN; Wlodarski P; Wasik MA
    Oncogene; 2007 Feb; 26(6):813-21. PubMed ID: 16909118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells.
    Shama J; Garcia-Medina R; Pouysségur J; Vial E
    Biochem Biophys Res Commun; 2008 Aug; 372(4):845-9. PubMed ID: 18533112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.
    Liu Q; Zhu H; Zhang C; Chen T; Cao X
    Oncoimmunology; 2017; 6(1):e1245265. PubMed ID: 28197363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
    Caunt CJ; Sale MJ; Smith PD; Cook SJ
    Nat Rev Cancer; 2015 Oct; 15(10):577-92. PubMed ID: 26399658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1).
    Dwivedi Y; Rizavi HS; Zhang H; Roberts RC; Conley RR; Pandey GN
    Int J Neuropsychopharmacol; 2009 Nov; 12(10):1337-54. PubMed ID: 19835659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CInQ-03, a novel allosteric MEK inhibitor, suppresses cancer growth in vitro and in vivo.
    Kim DJ; Lee MH; Reddy K; Li Y; Lim DY; Xie H; Lee SY; Yeom YI; Bode AM; Dong Z
    Carcinogenesis; 2013 May; 34(5):1134-43. PubMed ID: 23354306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and characterization of two distinct human extracellular signal-regulated kinase activator kinases, MEK1 and MEK2.
    Zheng CF; Guan KL
    J Biol Chem; 1993 May; 268(15):11435-9. PubMed ID: 8388392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Leydig cell MEK/ERK pathway is critical for maintaining a functional population of adult Leydig cells and for fertility.
    Yamashita S; Tai P; Charron J; Ko C; Ascoli M
    Mol Endocrinol; 2011 Jul; 25(7):1211-22. PubMed ID: 21527500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.
    Ohren JF; Chen H; Pavlovsky A; Whitehead C; Zhang E; Kuffa P; Yan C; McConnell P; Spessard C; Banotai C; Mueller WT; Delaney A; Omer C; Sebolt-Leopold J; Dudley DT; Leung IK; Flamme C; Warmus J; Kaufman M; Barrett S; Tecle H; Hasemann CA
    Nat Struct Mol Biol; 2004 Dec; 11(12):1192-7. PubMed ID: 15543157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.